THRX
Price:
$4.065
Market Cap:
$181.50M
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorpo...[Read more]
Industry
Biotechnology
IPO Date
2021-10-07
Stock Exchange
NASDAQ
Ticker
THRX
According to Theseus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -24.51%. This represents a change of 296.74% compared to the average of -6.18% of the last 4 quarters.
The mean historical ROE of Theseus Pharmaceuticals, Inc. over the last ten years is 19.40%. The current -24.51% ROE has changed -226.31% with respect to the historical average. Over the past ten years (40 quarters), THRX's ROE was at its highest in in the June 2021 quarter at 15.45%. The ROE was at its lowest in in the December 2022 quarter at -7.43%.
Average
19.40%
Median
11.96%
Minimum
-22.68%
Maximum
76.36%
Discovering the peaks and valleys of Theseus Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 104.64%
Maximum Annual ROE = 76.36%
Minimum Annual Increase = -131.65%
Minimum Annual ROE = -22.68%
Year | ROE | Change |
---|---|---|
2022 | -22.68% | 104.64% |
2021 | -11.08% | -131.65% |
2020 | 35.01% | -54.15% |
The current ROE of Theseus Pharmaceuticals, Inc. (THRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
0.42%
5-year avg
19.40%
10-year avg
19.40%
Theseus Pharmaceuticals, Inc.’s ROE is greater than aTyr Pharma, Inc. (-56.83%), greater than Relay Therapeutics, Inc. (-43.66%), greater than Century Therapeutics, Inc. (-65.37%), greater than Blueprint Medicines Corporation (-85.25%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Enliven Therapeutics, Inc. (-29.31%), greater than Immuneering Corporation (-66.03%), greater than Gracell Biotechnologies Inc. (-37.20%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Design Therapeutics, Inc. (-18.48%), greater than Erasca, Inc. (-131.94%), less than X4 Pharmaceuticals, Inc. (32.93%), less than Galera Therapeutics, Inc. (21.95%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than HOOKIPA Pharma Inc. (-51.77%), greater than Mersana Therapeutics, Inc. (-333.91%), greater than Arcus Biosciences, Inc. (-42.86%),
Company | ROE | Market cap |
---|---|---|
-56.83% | $131.12M | |
-43.66% | $835.47M | |
-65.37% | $123.69M | |
-85.25% | $5.47B | |
-21.96% | $77.28M | |
-28.37% | $1.04B | |
-29.31% | $1.01B | |
-66.03% | $34.99M | |
-37.20% | $989.87M | |
-70.40% | $349.21M | |
-18.48% | $264.42M | |
-131.94% | $807.96M | |
32.93% | $109.78M | |
21.95% | $4.08M | |
-39.58% | $549.60M | |
-122.70% | $1.25B | |
-51.77% | $159.50M | |
-333.91% | $165.61M | |
-42.86% | $1.44B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Theseus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Theseus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Theseus Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Theseus Pharmaceuticals, Inc. (THRX)?
What is the highest ROE for Theseus Pharmaceuticals, Inc. (THRX)?
What is the 3-year average ROE for Theseus Pharmaceuticals, Inc. (THRX)?
What is the 5-year average ROE for Theseus Pharmaceuticals, Inc. (THRX)?
How does the current ROE for Theseus Pharmaceuticals, Inc. (THRX) compare to its historical average?